Ruxolitinib cream for non-segmental vitiligo in people 12+

NICE Technology Appraisals

Published March 17th, 2026

Detected March 17th, 2026

Summary

NICE has published updated technology appraisal guidance (TA1140) on ruxolitinib cream for treating non-segmental vitiligo in individuals aged 12 and over. This guidance replaces previous recommendations and includes information on commercial arrangements for the drug.

View original document View source feed page

What changed

NICE has issued updated technology appraisal guidance (TA1140) concerning the use of ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in individuals aged 12 years and older. This guidance supersedes TA1088 and provides evidence-based recommendations. It also outlines commercial access arrangements, directing NHS organisations to the CAP Portal and other organisations to a specific email address for details.

Healthcare providers should consider these recommendations when treating eligible patients, alongside patient preferences and values. The guidance emphasizes that its application is at the discretion of health professionals and patients. It also reminds users to report adverse events via the Yellow Card Scheme and highlights the responsibilities of commissioners and providers to ensure funding and consider environmental impact.

What to do next

Review updated NICE technology appraisal guidance TA1140 regarding ruxolitinib cream.
Consult with patients on treatment options for non-segmental vitiligo, considering the NICE recommendations.
Report any adverse events associated with ruxolitinib cream via the Yellow Card Scheme.

Source document (simplified)

Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over

Technology appraisal guidance
TA1140
Published:

17 March 2026

Download guidance (PDF)

Overview

Evidence-based recommendations on ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in people 12 years and over.

Last reviewed: 17 March 2026

This guidance updates and replaces NICE technology appraisal guidance on ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088).

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Commercial arrangement

There is a commercial access arrangement for ruxolitinib cream. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact uk_enquiries@incyte.com for details.

Guidance development process

How we develop NICE technology appraisal guidance

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.